Cancer NetworkOriginal article
<![CDATA[02 Ten-Year Outcomes of Hypofractionated Breast/Chest Wall Radiotherapy With Simultaneous Integrated Boost (SIB) in Patients Under-Represented on Clinical Trials]]>
Data ReadoutpositivePositive
AI Analysis
Summary
A 10-year prospective pilot study of 74 breast/chest wall cancer patients treated with hypofractionated radiotherapy with simultaneous integrated boost demonstrated strong long-term efficacy with 93% local recurrence-free survival and favorable safety profile in underrepresented patient populations.
Clinical Trial Data
Primary Endpoint
Met
Patients
74
Outcome Details
10-year outcomes from prospective pilot of hypofractionated breast/chest wall radiotherapy with SIB in 74 under-represented patients showed 93.1% local recurrence-free survival, 94.2% distant metastasis-free survival, and 89.2% overall survival with no grade 3 brachial plexopathy or significant lymphedema
Importance:4/10
Sentiment:
0.60
oncologybreast cancerradiotherapyclinical triallong-term outcomesunderrepresented populations
Related Companies
Read the original article
Published by Cancer Network on July 16, 2026 10:30 PM